Cargando…

Berberine Could Ameliorate Cardiac Dysfunction via Interfering Myocardial Lipidomic Profiles in the Rat Model of Diabetic Cardiomyopathy

Background: Diabetic cardiomyopathy (DCM) is considered to be a distinct clinical entity independent of concomitant macro- and microvascular disorders, which is initiated partly by disturbances in energy substrates. This study was to observe the dynamic modulations of berberine in DCM rats and explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Shifen, Zhang, Shuofeng, Chen, Zhirong, Zhang, Rong, Tian, Linyue, Cheng, Long, Shang, Fei, Sun, Jianning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090155/
https://www.ncbi.nlm.nih.gov/pubmed/30131709
http://dx.doi.org/10.3389/fphys.2018.01042
_version_ 1783347146357997568
author Dong, Shifen
Zhang, Shuofeng
Chen, Zhirong
Zhang, Rong
Tian, Linyue
Cheng, Long
Shang, Fei
Sun, Jianning
author_facet Dong, Shifen
Zhang, Shuofeng
Chen, Zhirong
Zhang, Rong
Tian, Linyue
Cheng, Long
Shang, Fei
Sun, Jianning
author_sort Dong, Shifen
collection PubMed
description Background: Diabetic cardiomyopathy (DCM) is considered to be a distinct clinical entity independent of concomitant macro- and microvascular disorders, which is initiated partly by disturbances in energy substrates. This study was to observe the dynamic modulations of berberine in DCM rats and explore the changes of lipidomic profiles of myocardial tissue. Methods: Sprague-Dawley (SD) rats were fed high-sucrose and high-fat diet (HSHFD) for totally 22 weeks and intraperitoneally (i.p.) injected with 30 mg/kg of streptozotocin (STZ) at the fifth week to induce DCM. Seventy-two hours after STZ injection, the rats were orally given with berberine at 10, 30 mg/kg and metformin at 200 mg/kg, respectively. Dynamic changes of cardiac function, heart mass ratios and blood lipids were observed at f 4, 10, 16, and 22, respectively. Furthermore, lipid metabolites in myocardial tissue at week 16 were profiled by the ultra-high-performance liquid chromatography coupled to a quadruple time of flight mass spectrometer (UPLC/Q-TOF/MS) approach. Results: Berberine could protect against cardiac diastolic and systolic dysfunctions, as well as cardiac hypertrophy, and the most effective duration is with 16-week of administration. Meanwhile, 17 potential biomarkers of phosphatidylcholines (PCs), phosphatidylethanolamines (PEs) and sphingolipids (SMs) of DCM induced by HSFD/STZ were identified. The perturbations of lipidomic profiles could be partly reversed with berberine intervention, i.e., PC (16:0/20:4), PC (18:2/0:0), PC (18:0/18:2), PC (18:0/22:5), PC (20:4/0:0), PC (20:4/18:0), PC (20:4/18:1), PC (20:4/20:2), PE (18:2/0:0), and SM (d18:0/16:0). Conclusions: These results indicated a close relationship between PCs, PEs and SMs and cardiac damage mechanisms during development of DCM. The therapeutic effects of berberine on DCM are partly caused by interferences with PCs, PEs, and SMs metabolisms.
format Online
Article
Text
id pubmed-6090155
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60901552018-08-21 Berberine Could Ameliorate Cardiac Dysfunction via Interfering Myocardial Lipidomic Profiles in the Rat Model of Diabetic Cardiomyopathy Dong, Shifen Zhang, Shuofeng Chen, Zhirong Zhang, Rong Tian, Linyue Cheng, Long Shang, Fei Sun, Jianning Front Physiol Physiology Background: Diabetic cardiomyopathy (DCM) is considered to be a distinct clinical entity independent of concomitant macro- and microvascular disorders, which is initiated partly by disturbances in energy substrates. This study was to observe the dynamic modulations of berberine in DCM rats and explore the changes of lipidomic profiles of myocardial tissue. Methods: Sprague-Dawley (SD) rats were fed high-sucrose and high-fat diet (HSHFD) for totally 22 weeks and intraperitoneally (i.p.) injected with 30 mg/kg of streptozotocin (STZ) at the fifth week to induce DCM. Seventy-two hours after STZ injection, the rats were orally given with berberine at 10, 30 mg/kg and metformin at 200 mg/kg, respectively. Dynamic changes of cardiac function, heart mass ratios and blood lipids were observed at f 4, 10, 16, and 22, respectively. Furthermore, lipid metabolites in myocardial tissue at week 16 were profiled by the ultra-high-performance liquid chromatography coupled to a quadruple time of flight mass spectrometer (UPLC/Q-TOF/MS) approach. Results: Berberine could protect against cardiac diastolic and systolic dysfunctions, as well as cardiac hypertrophy, and the most effective duration is with 16-week of administration. Meanwhile, 17 potential biomarkers of phosphatidylcholines (PCs), phosphatidylethanolamines (PEs) and sphingolipids (SMs) of DCM induced by HSFD/STZ were identified. The perturbations of lipidomic profiles could be partly reversed with berberine intervention, i.e., PC (16:0/20:4), PC (18:2/0:0), PC (18:0/18:2), PC (18:0/22:5), PC (20:4/0:0), PC (20:4/18:0), PC (20:4/18:1), PC (20:4/20:2), PE (18:2/0:0), and SM (d18:0/16:0). Conclusions: These results indicated a close relationship between PCs, PEs and SMs and cardiac damage mechanisms during development of DCM. The therapeutic effects of berberine on DCM are partly caused by interferences with PCs, PEs, and SMs metabolisms. Frontiers Media S.A. 2018-08-02 /pmc/articles/PMC6090155/ /pubmed/30131709 http://dx.doi.org/10.3389/fphys.2018.01042 Text en Copyright © 2018 Dong, Zhang, Chen, Zhang, Tian, Cheng, Shang and Sun. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Dong, Shifen
Zhang, Shuofeng
Chen, Zhirong
Zhang, Rong
Tian, Linyue
Cheng, Long
Shang, Fei
Sun, Jianning
Berberine Could Ameliorate Cardiac Dysfunction via Interfering Myocardial Lipidomic Profiles in the Rat Model of Diabetic Cardiomyopathy
title Berberine Could Ameliorate Cardiac Dysfunction via Interfering Myocardial Lipidomic Profiles in the Rat Model of Diabetic Cardiomyopathy
title_full Berberine Could Ameliorate Cardiac Dysfunction via Interfering Myocardial Lipidomic Profiles in the Rat Model of Diabetic Cardiomyopathy
title_fullStr Berberine Could Ameliorate Cardiac Dysfunction via Interfering Myocardial Lipidomic Profiles in the Rat Model of Diabetic Cardiomyopathy
title_full_unstemmed Berberine Could Ameliorate Cardiac Dysfunction via Interfering Myocardial Lipidomic Profiles in the Rat Model of Diabetic Cardiomyopathy
title_short Berberine Could Ameliorate Cardiac Dysfunction via Interfering Myocardial Lipidomic Profiles in the Rat Model of Diabetic Cardiomyopathy
title_sort berberine could ameliorate cardiac dysfunction via interfering myocardial lipidomic profiles in the rat model of diabetic cardiomyopathy
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090155/
https://www.ncbi.nlm.nih.gov/pubmed/30131709
http://dx.doi.org/10.3389/fphys.2018.01042
work_keys_str_mv AT dongshifen berberinecouldamelioratecardiacdysfunctionviainterferingmyocardiallipidomicprofilesintheratmodelofdiabeticcardiomyopathy
AT zhangshuofeng berberinecouldamelioratecardiacdysfunctionviainterferingmyocardiallipidomicprofilesintheratmodelofdiabeticcardiomyopathy
AT chenzhirong berberinecouldamelioratecardiacdysfunctionviainterferingmyocardiallipidomicprofilesintheratmodelofdiabeticcardiomyopathy
AT zhangrong berberinecouldamelioratecardiacdysfunctionviainterferingmyocardiallipidomicprofilesintheratmodelofdiabeticcardiomyopathy
AT tianlinyue berberinecouldamelioratecardiacdysfunctionviainterferingmyocardiallipidomicprofilesintheratmodelofdiabeticcardiomyopathy
AT chenglong berberinecouldamelioratecardiacdysfunctionviainterferingmyocardiallipidomicprofilesintheratmodelofdiabeticcardiomyopathy
AT shangfei berberinecouldamelioratecardiacdysfunctionviainterferingmyocardiallipidomicprofilesintheratmodelofdiabeticcardiomyopathy
AT sunjianning berberinecouldamelioratecardiacdysfunctionviainterferingmyocardiallipidomicprofilesintheratmodelofdiabeticcardiomyopathy